Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Samsara BioCapital, LLC

Q2 2023 · 13F-HR

Samsara BioCapital, LLCholdings as filed

Filed 2023-08-14 · accession 0001104659-23-091467

$569.7M
Reported value
47
Positions
2023-06-30
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
16961L106CHINOOK THERAPEUTICS INC$198.3M34.8%5,161,888CommonSOLE
603170101MLYSMINERALYS THERAPEUTICS INC$77.1M13.5%4,519,361CommonSOLE
00445A100ACELYRIN INC$47.2M8.28%2,256,022CommonSOLE
80706P103SRRKSCHOLAR ROCK HLDG CORP$34.7M6.09%4,598,828CommonSOLE
38870X104GRPHGRAPHITE BIO INC$22.0M3.86%8,459,314CommonSOLE
03940C100ACLXGBXARCELLX INC$19.4M3.41%613,921CommonSOLE
05337M104AVADEL PHARMACEUTICALS PLC$15.9M2.80%967,527CommonSOLE
98985Y108ZYMEZYMEWORKS INC$12.6M2.21%1,458,875CommonSOLE
46583P102IVERIC BIO INC$12.1M2.13%308,151CommonSOLE
55234L105LYRAGBPLYRA THERAPEUTICS INC$11.4M2.01%2,780,261CommonSOLE
43157M102HILLEVAX INC$10.3M1.81%599,274CommonSOLE
23345J104DICE THERAPEUTICS INC$9.4M1.65%202,773CommonSOLE
869367102SUTRO BIOPHARMA INC$7.8M1.37%1,675,579CommonSOLE
925050106VRNAVERONA PHARMA PLC$7.3M1.29%347,500CommonSOLE
00461U105ACRSACLARIS THERAPEUTICS INC$7.2M1.27%696,171CommonSOLE
45845P108INTERCEPT PHARMACEUTICALS IN$7.1M1.24%640,688CommonSOLE
74168J101PRMEPRIME MEDICINE INC$6.9M1.21%470,304CommonSOLE
65487U108NKTXNKARTA INC$6.3M1.10%2,868,035CommonSOLE
713317105PEPGPEPGEN INC$5.8M1.02%651,050CommonSOLE
76243J105RYTMRHYTHM PHARMACEUTICALS INC$5.7M1.00%345,293CommonSOLE
45258D105IMCRIMMUNOCORE HLDGS PLC$4.9M0.85%80,963CommonSOLE
N44445109IMTXIMMATICS N.V$4.6M0.80%396,000CommonSOLE
47103J105JANXJANUX THERAPEUTICS INC$4.3M0.75%360,414CommonSOLE
30233G209EYPTEYEPOINT PHARMACEUTICALS INC$3.8M0.66%432,000CommonSOLE
24343R106DECIBEL THERAPEUTICS INC$3.1M0.54%801,629CommonSOLE
87184Q206SYRSSYROS PHARMACEUTICALS INC$2.8M0.49%881,450CommonSOLE
75082Q105RAIN ONCOLOGY INC$2.4M0.43%2,034,552CommonSOLE
23954D109DAWNGBXDAY ONE BIOPHARMACEUTICALS I$2.3M0.41%196,425CommonSOLE
87583X109TNGXTANGO THERAPEUTICS INC$2.1M0.37%630,000CommonSOLE
449778109IOBTQIO BIOTECH INC$2.0M0.35%1,008,437CommonSOLE
52187K200CYPHLEAP THERAPEUTICS INC$1.9M0.33%602,203CommonSOLE
880881107430TERNS PHARMACEUTICALS INC$1.8M0.31%202,348CommonSOLE
4495851081K0IGM BIOSCIENCES INC$1.4M0.25%154,664CommonSOLE
097702104BOLT1EURBOLT BIOTHERAPEUTICS INC$1.3M0.24%1,049,153CommonSOLE
28623U101ELEVATION ONCOLOGY INC$1.3M0.22%830,565CommonSOLE
918385105VTV THERAPEUTICS INC$1.2M0.21%1,635,509CommonSOLE
45783C101INSTIL BIO INC$985,3420.17%1,788,280CommonSOLE
92765F108RYIVIRACTA THERAPEUTICS INC$972,4900.17%689,709CommonSOLE
01671P100ALLKGUSDALLAKOS INC$750,3080.13%172,089CommonSOLE
00773J103AEGLEA BIOTHERAPEUTICS INC$398,1160.07%883,720CommonSOLE
019818103ALLOVIR INC$279,9420.05%82,336CommonSOLE
04635X102CATBUSDASTRIA THERAPEUTICS INC$208,2500.04%25,000CommonSOLE
808644108SCIENCE 37 HOLDINGS INC$191,2500.03%900,000CommonSOLE
670002401NVAXNOVAVAX INC$157,8430.03%21,244CommonSOLE
50107A104KRON1USDKRONOS BIO INC$134,3850.02%78,131CommonSOLE
67080N119NUVB/WSNUVATION BIO INC$22,0520.00%133,333CommonSOLE
86889P117SRZNWSURROZEN INC$5,5200.00%99,999CommonSOLE

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.